Eiger BioPharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Eiger Biopharmaceuticals

11/05/2023 21:23

* Eiger BioPharmaceuticals Inc  EIGR.OQ  reported a
quarterly
adjusted loss of 52 cents​​ per share for the quarter ended in
March. The mean expectation of three analysts for the quarter
was for a loss of 47 cents per share.
    * Revenue rose 54.1% to $4.12 million from a year ago;
analysts
expected $4.16 million. 
    * Eiger BioPharmaceuticals Inc's reported EPS for the
quarter was
a loss of 52 cents​.
    * The mean earnings estimate of analysts had fallen by
about 5.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Eiger BioPharmaceuticals Inc shares had risen by 29.3%
this
quarter and lost 1.7% so far this year.
    * The company reported a quarterly loss of $22.78 million.
    * Wall Street's median 12-month price target for Eiger
BioPharmaceuticals Inc is $5.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 08:23 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.47          -0.52          Missed
 Dec. 31 2022      -0.54          -0.57          Missed
 Sep. 30 2022      -0.52          -0.62          Missed
 Jun. 30 2022      -0.61          -0.51          Beat